What is the difference between translation and localization in clinical trials?

Translation converts content from one language to another while preserving its original meaning. Localization adapts that content for a specific region, including tone, structure, format, and ease of use.

When is localization necessary in a clinical trial?

Localization is most important for participant-facing materials and content that needs to be understood quickly and used correctly. It helps materials feel natural, culturally appropriate, and effective in real-world study settings.

Can translation alone be sufficient for clinical trial materials?

Yes, translation is sufficient for highly technical or regulatory content where precision and consistency are the primary priorities. However, it may not ensure that materials are easily understood or usable across different regions.

Why does localization matter for patient understanding and engagement?

Localization improves clarity and relevance by aligning materials with how participants interpret and process information. This helps reduce confusion, supports informed consent, and minimizes the need for additional explanation at the site level.

Do clinical trials need both translation and localization?

In many global studies, yes. Translation provides linguistic accuracy and consistency. Localization helps ensure participant-facing and site-facing materials are understandable, appropriate, and practical across regions. Together, they support both compliance and consistent study execution.

Category:

Participant Engagement

Sites in Europe: at the EU Site Solutions Summit

by Melynda Geurts November 18, 2015

written by Melynda Geurts

Nice, France recently played host to the inaugural SCRS European Site Solutions Summit. Nestled among the infamous Promenade des Anglais, the Summit hosted over 100 attendees from various sites around the globe.

During the Summit discussions focused on Collaborating for the Future to the New EU Clinical Trial Regulation and its potential impact on sites and the European Face of Clinical Trials. INC Research continued their sponsorship of the networking event, which was met with good and lively conversations. Great connections were sure to be had.

I was honored to attend and represent DAC as one of the Global Impact Partners and summit sponsor. We anxiously await the announcement of the 2nd European Summit and gathering with colleagues across the pond.

November 18, 2015 0 comments

Clinical Trial Business Insights Participant Engagement
Talking Recruitment with Small/Mid BioPharm CMOs at CMO Summit – West

by Dan McDonald November 12, 2015
by Dan McDonald November 12, 2015

I had the honor of attending and presenting at the CMO Summit – West earlier this week in Burlingame, CA. Attended by 75-80 industry executives – primarily consisting of Chief Medical Officers, heads of clinical development and leaders from the financial community – the CMO …

0 Facebook Twitter Linkedin Email
Clinical Trial Business Insights Participant Engagement
25 Reasons People Aren’t Enrolling in Your Clinical Trial

by Felicia Fuller October 29, 2015
by Felicia Fuller October 29, 2015

25 Reasons People Aren’t Enrolling in Your Clinical Trial We’ve long heard about the lack of participation in clinical trials and how slow poor enrollment dogs many, if not most, clinical trials today. What follows are the 25 most common reasons people choose not to …

0 Facebook Twitter Linkedin Email
Participant Engagement
Cultivating Site Partnerships for Maximum Recruitment Success

by Diana Foster October 13, 2015
by Diana Foster October 13, 2015

There is a lot of emphasis today on the relationship between sites, sponsors, and their CRO partners. Site sustainability and strong partnerships that help cultivate the success of clinical research sites are of critical importance to the conduct of trials. With enrollment success at the …

0 Facebook Twitter Linkedin Email
Clinical Trial Business Insights Participant Engagement
DAC Wins Best Headline in Rethink Research Awards, MAGI 2015

by Melynda Geurts October 12, 2015
by Melynda Geurts October 12, 2015

This morning, at MAGI’s 2015 Clinical Research Conference in San Diego, the winners of the Rethink Research Awards (a campaign to recognize the best concepts in clinical research rebranding, in hopes of raising public awareness and involvement) were announced. If you’re not familiar with it, …

0 Facebook Twitter Linkedin Email
Clinical Trial Business Insights Participant Engagement
Dpharm 2015: Challenging the Status Quo of Drug Development

by Dan McDonald September 25, 2015
by Dan McDonald September 25, 2015

Forward Thinkers Gather to Challenge the Status Quo in Drug Development A Dpharm 2015 recap I had the honor of representing Imperial and speaking at the “Disruptive Innovations – US” conference, which took place in Boston on September 10th and 11th. The event, now in …

0 Facebook Twitter Linkedin Email
Participant Engagement
8 Critical Factors for Boosting Site Enrollment Out of the Gate

by Melynda Geurts September 15, 2015
by Melynda Geurts September 15, 2015

We all know that delays in patient recruitment and enrollment can be costly, and it is critical to minimize as many delays as possible from study initiation to when the sites are actually able to enroll. If you don’t get a head start on site …

0 Facebook Twitter Linkedin Email
Participant Engagement
Leveraging Mobile Technology for Patient Retention

by Melynda Geurts September 8, 2015
by Melynda Geurts September 8, 2015

In my last post, I provided a quick overview of the 3 primary trends that are currently shifting the patient recruitment and retention landscape. Today, I’d like to dive deeper into one of those trends: the use of mobile technology for patient retention. Those of us …

0 Facebook Twitter Linkedin Email
Participant Engagement
Patient Recruitment & Retention Trends: How They Can Impact Your Site

by Melynda Geurts September 1, 2015
by Melynda Geurts September 1, 2015

The clinical trial industry is highly dynamic; there are many moving parts that seem to constantly be revised, enhanced, and morphed into the “next big thing.” Maneuvering through these ever-changing processes adds to the already existing complexities of conducting and managing clinical trials. There are …

0 Facebook Twitter Linkedin Email
Participant Engagement
The Many Faces of Clinical Trials

by Melynda Geurts August 19, 2015
by Melynda Geurts August 19, 2015

In hopes of pushing the envelope of modern medicine, clinical trials are growing increasingly complex. With more interested parties, complexities take on an entirely different meaning. Clinical trials typically involve five main stakeholders, and each group has its own views and motivations. Here is what people …

0 Facebook Twitter Linkedin Email